ProfoundBio Announces Presentation on Novel, Proprietary Linker-Drug Technology to Enable Antibody-Drug Conjugates (ADCs) with an Expanded Therapeutic Window at the AACR-NCI-EORTC International Conference

WOODINVILLE, Wash. and SUZHOU, China, Oct. 7, 2021 /PRNewswire/ -- ProfoundBio announces that preclinical data from its novel, proprietary ADC technology platform are being presented at the 2021 Molecular Targets and Cancer Therapeutics conference hosted by the American Association for...

from PR Newswire: https://ift.tt/2YxtX2E